On International Women’s Day, we honor all our women team members at Cartesian, whose accomplishments and contributions are integral to our progress in pioneering possibilities in #immunology, and continue to support fair opportunities and the advancement of gender equality in the workplace. #IWD2025
Cartesian Therapeutics
Biotechnology Research
Frederick, Maryland 5,304 followers
Pioneering RNA cell therapy for autoimmune disease
About us
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systematic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Frederick, Maryland
- Type
- Public Company
- Founded
- 2016
- Specialties
- Immunotherapy, Oncology, Molecular Biology, Immunology, Myasthenia Gravis, ARDS, Cell Therapy, NETs, Gene Therapy, Cancer Research, multiple myeloma, SLE, mRNA, CAR-T, Systemic lupus erythematosus, Autoimmunity, Autoimmune Disease, and Lupus
Locations
-
Primary
7495 New Horizon Way
Frederick, Maryland 21703, US
Employees at Cartesian Therapeutics
-
Christopher M. Jewell
Chief Scientific Officer, Cartesian Therapeutics | MPower Professor and Institute Professor of Translational Engineering | Biotechnology Consultant
-
Heng Xu
Research Scientist at Cartesian Therapeutics
-
Jessica Keliher, SPHR
Chief People Officer & Executive Leadership Coach
-
Cindy Douglas
Executive Office Administration Manager
Updates
-
In celebration of #EmployeeAppreciationDay, we’re expressing gratitude for our incredible team. Your dedication to our patients and commitment to pioneering possibilities in #immunology makes Cartesian an inspiring and rewarding place to work!
-
Looking forward to attending three upcoming investor conferences, where we’re discussing exciting company milestones ahead as we work to expand the reach of #celltherapy to #autoimmunedisease. Information here: https://bit.ly/3X6fs0K
-
-
Today we celebrate International Day of Women and Girls in Science, recognizing the talent, innovation and commitment of #WomeninSTEM. Hear from two of new Cartesian team members: Kelli Tea, MBA and Eva Rybak on the importance of building up the next generation of women scientists. #IDWGS
-
Cartesian received agreement from the #FDA under a Special Protocol Assessment (SPA) on the design of our Phase 3 AURORA trial for Descartes-08, our lead mRNA cell therapy candidate in #myastheniagravis, supporting a path towards potential approval. Learn more: https://bit.ly/4jv23sR
-
-
Join us in congratulating Emily English, PhD on her new role as Chief Operations Officer at Cartesian. Emily’s significant contributions have been instrumental in our progress towards developing cell therapies for patients with #autoimmunediseases, including establishing our wholly-owned manufacturing site as we move into Phase 3 AURORA trial of Descartes-08 in #myastheniagravis. We look forward to continuing our important work together!
-
-
We are excited to be in-person in San Francisco this year during #JPM2025 and look forward to connecting with the #biotech community and discuss Cartesian’s recent progress and strategic priorities in 2025 across our pipeline of mRNA cell therapies for #autoimmunediseases.
-
-
Cartesian’s new website is live! We’ve updated our design to reflect the evolution of Cartesian and where we are today in our journey of expanding the reach of cell therapy to #autoimmune diseases. Check out our latest updates: https://lnkd.in/en9Ni98J
-
We’ve highlighted our recent progress and outlined Cartesian’s 2025 strategic priorities across our pipeline of mRNA cell therapy candidates for the treatment of #autoimmune diseases. Learn more about what we have in store for this year: https://bit.ly/3DT8QMN
-
We had a great time at our holiday party recently, surrounded by our fellow team members and got into the festive spirit. Thanks to our partnership with Frederick Rescue Mission, we were able to spread joy and kindness by hosting a food drive, and collected over three shopping carts of groceries. These donations will help stock the Mission’s “store,” where they offer free groceries to those in need in our community.
-